Insulin icodec/Semaglutide
- Generic Name
- Insulin icodec/Semaglutide
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 474
- Registration Number
- NCT06269107
- Locations
- 🇺🇸
Methodist Phys. Clinic, Omaha, Nebraska, United States
🇺🇸Albuquerque Clin Trials, Inc., Albuquerque, New Mexico, United States
🇺🇸Albany Medical College - Endo, Albany, New York, United States
A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT05435677
- Locations
- 🇨🇳
Peking University Third Hospital, Northern branch-Phase I, Beijing, Beijing, China
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1291
- Registration Number
- NCT05352815
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇵🇹Unidade Local De Saude Da Regiao De Aveiro E.P.E., Aveiro, Portugal
🇳🇴St. Olavs Hospital HF, Trondheim, Norway
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 683
- Registration Number
- NCT05259033
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇨🇳Zhu Xianyi Memorial Hospital of Tianjin Medical University-Endocrinology, Tianjin, Tianjin, China
🇺🇸Pri Med Grp dba/Gil Ctr Fam, Gilbert, Arizona, United States
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 679
- Registration Number
- NCT05013229
- Locations
- 🇺🇸
Endeavor Health, Skokie, Illinois, United States
🇺🇸Andres Garcia-Zuniga, MD, P.A, Laredo, Texas, United States
🇫🇷Centre de Recherche Clinique Portes Du Sud, Venissieux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.